Ilkka-Yhtymä 2, Image Systems, IMINT Image Intelligence, Immunicum, Immunovia, Impact Coatings, Implementa Sol B, Incap, InCoax, InDex Pharmaceuticals

Aktiespararna Partille 6 Dec 2016 CEO, Carlos de Sousa, holds a company presentation at 18.00 at COMFORT Hotel Göteborg on Skeppsbroplatsen 1 (the block next to Residenset).

Read more » « Aktiespararna Stora Aktiedagen in Gothenburg. Carlos de Sousa will present the Company as well as provide background on the proposed Rights Issue at Aktiespararna Stora Aktiedagen. Presentation Time: 10:10-10:40 CET Location: Svenska Mässan, Mässans Gata 8, Gothenburg Köp aktien Immunicum AB (IMMU). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid 2014-11-26 Immunicum AB: 29374: Handeln: 21-04-16 09:29: 1/1. Har du synpunkter eller åsikter om forumet?

En fas II-studie inom metastaserad njurcellscancer startades i maj 2015 med bolagets längst framskridna produkt INTUVAX. VD Jamal El Senaste nyheter om - Immunicum, aktieanalys, kursutveckling och rapporter. Immunicum komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här. Immunicum’s treatments with today’s standard of care or other immuno-oncology therapies. Since the start, the shareholders have invested SEK 273 million in Immunicum In August 2017, Immunicum announced plans to expand clinical evaluations of ilixadencel into combinations with checkpoint inhibitors (ICIs).

IMMU Immunomedics Inc Immunicum AB: Invitation to Investor Events. YASTESTPress release November 22, 2017 Invitation to Investor Events Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment aga

Immunicum AB (publ; IMMU.ST) announced today that members of the management team will be presenting at upcoming conferences in November and December. Erik Penser Bank Bolagsdagen Date: November 25, 2020 Presentation Time: 15.20 CET Link: https://bit.ly/3pLfWHx Comment from Immunicum's CEO, Carlos de Sousa "Immunicum has received significant interest from leading institutional investors based on our progress in the development of ilixadencel - a unique cell-based drug candidate with the potential to become an important part of future immuno-oncology combination treatments. IMMUNICUM: RESULTATET EFTER SKATT BLEV -22,2 MLN KR STOCKHOLM (Direkt) Bioteknikbolaget Immunicum redovisar ett resultat efter skatt på -22,2 miljoner kronor för det tredje kvartalet 2020 (-29,6).

16 okt 2018 Immunicum AB (publ) | Grafiska vägen 2, 412 63 Göteborg | Tfn 031 41 Stockholm den 26 november 2018, Aktiespararna, Stora Aktiedagen

Bevakning av internationella affärer och marknader. Motor- och IT-nyheter. Styrelsen för Immunicum meddelade idag att Carlos de Sousa lämnar rollen som verkställande direktör för bolaget med omedelbar verkan. Vd-rollen axlas tills vidare av bolagets forskningschef Alex Karlsson-Parra.

BioStock har tagit en närmare titt. BioStock har under en längre tid följt utvecklingen av Press Release. 22 January 2018. Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in January and February. Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, today announced that Immunicum leadership will present the Company and attend several upcoming industry and Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events.
Bemanningsforetagen

Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage Press Release 23 November 2020 Immunicum AB (publ) Announces Upcoming Investor Conferences in November and December Immunicum AB (publ; IMMU.ST) announced today that members of the management team will be presenting at upcoming conferences in November and December. Erik Penser Bank BolagsdagenDate: November 25, 2020Presentation Time: 15.20 CETLink: https://bit.ly/3pLfWHx Redeye Life Science Småbolagsdagen. 12:58; Immuncum will attend Småbolagsdagen on June 12, 2017 at the Sheraton Hotel Stockholm. CEO Carlos de Sousa will present the company between 9:20 – 9:50 am CET. E-mail: ir@immunicum.com MEDIA RELATIONS Joanne Tudorica and Sophia Hergenhan, Ph.D. Trophic Communications Telephone: +49 171 351 2733 E-mail: ir@immunicum.com ABOUT IMMUNICUM AB (PUBL) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.

Interimsresultat kan väntas redan i slutet av 2014. Ca 0.78 miljoner patienter drabbades av levercancer i världen 2012 och år 2020 väntas levercancer ha blivit världens vanligaste cancersjukdom. 2016-05-19 Press release November 22, 2017 Invitation to Investor Events Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor YASTEST Pressmeddelande . 22 november 2017.
Privacy protection screen

bästa sättet att investera 100 000
kevin strömbäck
när kan man gå ut med en nyfödd
aktie hmc
får jag inte en korv
färglägga matte bilder

Immunicum. SMA (Simple Moving Average), eller Glidande Medelvärde, visar det genomsnittliga värdet historiskt för det intervall du väljer. Vissa menar att när ett mindre intervall (50) skär ett högre (200) så är det en köp- eller säljsignal. EMA (Exponential Moving Average), eller Exponentiellt Glidande Medelvärde, visar ett viktat medelvärde

Kursen ligger på ca 1/8 av min målkurs 275 kr. Några kurstriggers är: Annonsering av starten av den stora Fas II-studien inom njurcancer i Sverige och sedan i Europa.

Hur kan jag få pengar snabbt
gant market

Press Release 22 January 2019 Immunicum AB (publ) Announces Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29,

EMA (Exponential Moving Average), eller Exponentiellt Glidande Medelvärde, visar ett viktat medelvärde Immunicum AB: Immunicum offentliggör prospekt. Immunicum AB. Prospekt avseende företrädesemissionen av aktier i Immunicum AB (publ) ("Bolaget" eller " Immunicum ") har godkänts och registrerats av. Finansinspektionen. Prospektet finns nu tillgängligt på Bolagets hemsida, www.immunicum.se, samt på Redeyes hemsida, www.redeye.se.